Stockreport

Adverum Biotechnologies Begins Patient Enrollment in the ADVANCE Phase 1/2 Clinical Trial for A1AT Deficiency

Adverum Biotechnologies, Inc.  (ADVM) 
Last adverum biotechnologies, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: adverum.gcs-web.com/investor-overview
PDF -- Patients to Receive Single-administration of Gene Therapy Candidate ADVM-043 ---- Company Expects to Report Preliminary Data in the Second Half of 2018 -- MENLO PARK [Read more]